Analyst Price Targets — TECH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 26, 2026 12:25 pm | Steven Etoch | Stephens | $73.00 | $71.16 | TheFly | Bio-Techne downgraded to Equal Weight from Overweight at Stephens |
| June 26, 2026 10:40 am | Catherine Ramsey Schulte | Robert W. Baird | $73.00 | $70.70 | TheFly | Bio-Techne price target raised to $73 from $49 at Baird |
| June 26, 2026 7:34 am | Justin Bowers | Deutsche Bank | $73.00 | $70.70 | StreetInsider | Deutsche Bank Downgrades Bio-Techne Corp. (TECH) to Hold |
| June 25, 2026 3:20 pm | Market Perform | Leerink Partners | $73.00 | $70.55 | TheFly | Bio-Techne downgraded to Market Perform from Outperform at Leerink |
| June 11, 2026 9:52 am | — | Piper Sandler | $65.00 | $52.50 | TheFly | Bio-Techne initiated with a Neutral at Piper Sandler |
| May 14, 2026 8:21 pm | — | RBC Capital | $62.00 | $44.74 | TheFly | Bio-Techne resumed with an Outperform at RBC Capital |
| May 7, 2026 12:07 pm | Daniel Markowitz | Evercore ISI | $50.00 | $49.27 | TheFly | Bio-Techne price target lowered to $50 from $54 at Evercore ISI |
| May 7, 2026 11:26 am | — | Stifel Nicolaus | $50.00 | $47.41 | TheFly | Bio-Techne price target lowered to $50 from $65 at Stifel |
| May 7, 2026 11:21 am | — | Robert W. Baird | $49.00 | $47.41 | TheFly | Bio-Techne price target lowered to $49 from $70 at Baird |
| February 5, 2026 12:58 pm | — | Stifel Nicolaus | $65.00 | $67.64 | TheFly | Bio-Techne price target raised to $65 from $60 at Stifel |
Latest News for TECH
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address…
BALA CYNWYD, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.
MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.
BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.